LONDON (Alliance News) - Biotechnology company SalvaRx Group PLC started trading on AIM on Tuesday after reversing into investment company 3Legs Resources PLC.
Shares in SalvaRx were trading at 33.9 pence on Tuesday, down 3.1% on the day.
SalvaRx, a cancer immunotherapy development company, owns a 61% stake in iOx, a company developing a series of cancer immunotherapy compounds.
"I am delighted to see SalvaRx's stock begin trading on AIM. I would like to thank both original and new shareholders for their support. We have clear goals and a strategy in place and with our ownership of iOx, we've already made significant progress," said Chief Executive Ian Walters.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.